NCT02166463 2026-03-17Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaNational Cancer Institute (NCI)Phase 3 Active not recruiting600 enrolled 14 charts 1 FDA